Evidence map›Paper›PMID 40391889›Full record

ArticlemBio2025

A protective and broadly binding antibody class engages the influenza virus hemagglutinin head at its stem interface.

Holly C Simmons, Joel Finney, Ryutaro Kotaki, Yu Adachi, Annie Park Moseman, Akiko Watanabe, Shengli Song, Lindsey R Robinson-McCarthy, Valerie Le Sage, Masayuki Kuraoka and 4 more

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Holly C Simmons *Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-2186-1494
Joel Finney *Department of Integrative Immunobiology, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-3755-8425
Ryutaro KotakiResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku, Tokyo, Japan.
Yu AdachiResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku, Tokyo, Japan.
Annie Park MosemanDepartment of Integrative Immunobiology, Duke University, Durham, North Carolina, USA.ORCID 0009-0004-5773-9487
Akiko WatanabeDepartment of Integrative Immunobiology, Duke University, Durham, North Carolina, USA.
Shengli SongDepartment of Surgery, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-0507-5194
Lindsey R Robinson-McCarthyCenter for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-8066-2770
Valerie Le SageCenter for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Masayuki KuraokaDepartment of Integrative Immunobiology, Duke University, Durham, North Carolina, USA.ORCID 0000-0001-8745-6614
E Ashley MosemanDepartment of Integrative Immunobiology, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-6064-6116
Garnett KelsoeDepartment of Integrative Immunobiology, Duke University, Durham, North Carolina, USA.
Yoshimasa TakahashiResearch Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku, Tokyo, Japan.ORCID 0000-0001-6342-4087
Kevin R McCarthyCenter for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-1016-6015

Funding

Virology CoreP01AI089618 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI STEPHEN COPLAN HARRISON · 2011 to 2026
$40.0M
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI STEVEN E EALICK · 2018 to 2026
$34.2M
Funds from the University of Pittsburgh Center for Vaccine ResearchJapan Agency for Medical Research and Development JP223fa727002National Institute of Allergy and Infectious Diseases AI089618NIAID NIH HHS P01 AI089618NIGMS NIH HHS P30 GM124165
6 · The paper itself

Abstract

Influenza infection and vaccination impart strain-specific immunity that protects against neither seasonal antigenic variants nor the next pandemic. However, antibodies directed to conserved sites can confer broad protection. Here, we identify and characterize a class of human antibodies that engage a previously undescribed, conserved epitope on the influenza hemagglutinin (HA) protein. Prototype antibody S8V1-157 binds at the normally occluded interface between the HA head and stem. Antibodies to this HA head-stem interface epitope are non-neutralizing IMPORTANCE: Antibodies to the influenza virus hemagglutinin (HA) protein confer the strongest protection against infection. Human antibodies elicited by infection and/or vaccination fail to protect against antigenically novel animal, pandemic, or human seasonal viruses. Improved vaccines are needed. We identify a novel class of antibodies that bind most divergent HA subtypes and all seasonal human HA antigenic variants tested. These antibodies confer protection from lethal influenza challenge in animal models. The corresponding epitope on the HA head is occluded by its interaction with the stem and is inaccessible in the well-resolved prefusion state. The immunogenicity of this head-stem interface indicates that poorly understood conformations of HA presenting widely conserved surfaces are explored in biochemical, cell-based, and

Indexed as

Antibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza A virusAnimalsAntibodies, NeutralizingEpitopesFemaleHumansInfluenza, HumanInfluenza VaccinesMiceOrthomyxoviridae InfectionsProtein BindingAntibodies, NeutralizingAntibodies, ViralEpitopesHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccinesantibody repertoireimmunologyinfluenzamonoclonal antibodiesprotein structure-functionvirology

Identifiers

PMID40391889
PMCPMC12153317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.